Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fulcrum Therapeutics Inc
(NQ:
FULC
)
9.170
+0.380 (+4.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulcrum Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
February 28, 2024
Via
Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Earnings Preview: Fulcrum Therapeutics
February 26, 2024
Via
Benzinga
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Preview: Fulcrum Therapeutics's Earnings
November 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Fulcrum Therapeutics
September 25, 2023
Via
Benzinga
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
MicroMarvet - Fulcrum Therapeutics - Confusing Projections And Recommendation
January 09, 2024
Revenue is estimated to be down 63.40% this year and down another 19.80% next year. Earnings are projected to increase 32.80% this year but be down 9.80% next year.
Via
Talk Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 09, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near the Top of Equities by Percentage Gain on 11/7
November 07, 2023
Via
Investor Brand Network
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
September 25, 2023
Via
Benzinga
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
September 14, 2023
San Diego, CA -- (SBWIRE) -- 09/14/2023 -- Certain directors of Fulcrum Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 07, 2023
Enrolled 260 patients; topline data expected in the fourth quarter of 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 24, 2023
Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847.
Via
Benzinga
Dollar Tree, Burlington Stores, Opera And Other Big Stocks Moving Lower On Thursday
August 24, 2023
U.S. stocks traded lower, with the Dow Jones falling over 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Fulcrum Therapeutics To Rally Around 120%? FDA Update Removes Overhang On Pivotal Program
August 23, 2023
Tuesday, the FDA lifted the clinical hold on Fulcrum Therapeutics Inc's (NASDAQ: FULC) Investigational New Drug (IND) application for FTX-6058 for the potential treatment of
Via
Benzinga
Exposures
Product Safety
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
August 22, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
August 23, 2023
Via
Benzinga
Dow Falls Over 100 Points; US Existing Home Sales Decline In July
August 22, 2023
U.S. stocks traded mixed midway through trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.32% to 34,354.22 while the NASDAQ rose 0.52% to 13,567.52. The S&P 500,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 22, 2023
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.